A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

LESSONS LEARNED: Treatment with the Aurora kinase A inhibitor yields often durable disease control, but limited tumor regression, in heavily pretreated patients with unresectable malignant pleural or peritoneal mesothelioma. In a limited sample size, MYC copy‐number gain or gene amplification, a can...

Descripción completa

Detalles Bibliográficos
Autores principales: Gay, Carl M., Zhou, Yanhong, Lee, J. Jack, Tang, Xi Ming, Lu, Wei, Wistuba, Ignacio I., Ferrarotto, Renata, Gibbons, Don L., Glisson, Bonnie S., Kies, Merrill S., Simon, George R., Heymach, John V., Tsao, Anne S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543335/
https://www.ncbi.nlm.nih.gov/pubmed/32608142
http://dx.doi.org/10.1634/theoncologist.2020-0610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543335/
https://www.ncbi.nlm.nih.gov/pubmed/32608142
http://dx.doi.org/10.1634/theoncologist.2020-0610

Ejemplares similares